Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftaroline fosamil versus ceftriaxone plus vancomycin for community-acquired bacterial pneumonia at risk for MRSA
2012-002182-35Phase 2Completed
- Sponsor
- Cerexa
- Start
- Jul 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftaroline fosamil, ceftriaxone, vancomycin, azithromycin in community acquired pneumonia (CAP), sponsored by Cerexa. Started Jul 2012; status: completed.
02
Drugs
ceftaroline fosamilceftriaxonevancomycinazithromycin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2012-002182-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002182-35.